Quarterly report pursuant to Section 13 or 15(d)

Share (Tables)

v3.22.1
Share (Tables)
 3 Months Ended
Mar. 31, 2022
Share-Based Payment Arrangement [Abstract]  
Schedule of Warrants

A summary of the Company’s warrants to purchase common stock activity is as follows:

 

    Shares Underlying Warrants     Weighted Average Exercise Price     Weighted Average Remaining Contractual Life (years)    

Aggregate

Intrinsic Value

  
Outstanding and exercisable at December 31, 2021     8,406,616     $ 2.74       3.40     $      -  
Granted     120,000       0.50                  
Cancelled     (120,000 )     2.83                  
Forfeited     (513,632 )     5.18                  
Outstanding at March 31, 2022     7,892,984     $ 2.54       2.37     $ -  
Schedule of Stock Option Activity

A summary of the Company’s stock option activity is as follows:

 

    Shares Underlying Options     Weighted Average Exercise Price     Weighted Average Remaining Contractual Life (years)    

Aggregate

Intrinsic Value

  
Outstanding at December 31, 2021     6,152,562     $ 2.71       7.45     $     -  
Granted     1,895,000       0.46                  
Forfeited     (583 )     0.98                  
Outstanding at March 31, 2022     8,046,979     $ 2.18       7.83     $ -  
Schedule of Stock Option Pricing Model Using Weighted Average Assumptions

The Company estimated the fair value of each stock option award using the Black-Scholes option pricing model based on the following weighted average assumptions:

 

    Three Months Ended
March 31,		  
    2022     2021  
Expected term, in years     5.8       5.7  
Expected volatility     99.37 %     106.90 %
Risk-free interest rate     2.00 %     0.71 %
Dividend yield     -       -  
Schedule of Restricted Stock Unit Awards Activity

A summary of the Company’s restricted stock unit awards activity is as follows:

 

    Number of Shares     Weighted Average Grant Date Fair Value  
Nonvested at December 31, 2021     502,513     $ 2.24  
Granted     365,000       0.45  
Vested     (211,831 )     2.07  
Nonvested at March 31, 2022     655,682     $ 1.30  
Schedule of Stock-based Compensation

The following table sets forth total non-cash share-based compensation for the issuance of common stock, options to purchase common stock, warrants to purchase common stock, and restricted stock unit awards by operating statement classification for the three months ended March 31, 2022 and 2021:

 

    2022     2021  
    Three Months ended
March 31,		  
    2022     2021  
Research and development   $ 97     $ 134  
Sales and marketing     58       117  
General and administrative     366       668  
Total   $ 521     $ 919